SPY308.08+2.53 0.83%
DIA257.85+2.58 1.01%
IXIC9,608.38+56.33 0.59%

Cantor Fitzgerald Maintains Overweight on Biohaven Pharmaceutical, Raises Price Target to $82

Cantor Fitzgerald maintains Biohaven Pharmaceutical (NYSE:BHVN) with a Overweight and raises the price target from $75 to $82.

Benzinga · 05/11/2020 15:37

Cantor Fitzgerald maintains Biohaven Pharmaceutical (NYSE:BHVN) with a Overweight and raises the price target from $75 to $82.